Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 317Rectal Neoplasms 235Stomach Neoplasms 209Pancreatic Neoplasms 137Colonic Neoplasms 94Neoplasm Metastasis 60Esophageal Neoplasms 57Neoplasms 40Biliary Tract Neoplasms 39Cholangiocarcinoma 31Carcinoma, Hepatocellular 30Gallbladder Neoplasms 29Breast Neoplasms 28Adenocarcinoma 22Bile Duct Neoplasms 21Locally Advanced Rectal Cancer 20Adenocarcinoma Of Esophagus 20Gastrointestinal Neoplasms 18Liver Neoplasms 17Esophageal Squamous Cell Carcinoma 17Colorectal Cancer Metastatic 15Carcinoma, Non-Small-Cell Lung 12Anus Neoplasms 12Parkinson Disease 4, Autosomal Dominant Lewy Body 11Digestive System Neoplasms 7Carcinoma 7Advanced Gastric Cancer 7Squamous Cell Carcinoma of Head and Neck 6Ovarian Neoplasms 6Klatskin Tumor 6

Interventions

Gemcitabine 4130-nm albumin-bound paclitaxel 2sintilimab 1nimotuzumab 1avelumab 1Taxes 1Oxaliplatin 1Leucovorin 1Irinotecan 1Hydroxychloroquine 1Fluorouracil 1Capecitabine 1Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Cancer Resectable × Capecitabine × Gastrointestinal × Clear all
NCT06888674 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

Zhejiang University

Phase 1/2 Not yet recruiting
60 enrolled
Gastrointestinal

Pancreatic Cancer Resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡